Background: The opioid crisis has led to a dramatic increase in the number of drug overdose deaths in the United States. Little is known about the effect of the opioid crisis on the kidney transplant donor pool, particularly on hepatitis C virus (HCV)-infected donors. Methods: This is a retrospective analysis of the data from the Organ Procurement and Transplantation Network from 2010 to 2016. We determined the changes in characteristics of kidney transplant donors and evaluated which changes may be directly related to the opioid crisis. Results: Between 2010 and 2016, we found a 26% increase in overall donors, including a 277% increase in the number of donors who died from drug overdose. Nineteen percent of donors who died of drug overdose had HCV infection. Donors who die from drug overdose and donors with HCV infection are younger, less likely to have diabetes or hypertension, and have favorable kidney donor profile index scores compared to average donors. Despite these favorable characteristics, HCV-infected donors appear to be notably underutilized, with substantially lower kidneys per donor being transplanted compared to HCV uninfected donors. Conclusion: The opioid crisis in the United States has substantially altered the kidney donor pool. Strategies to increase utilization of all potentially viable kidneys for transplant are needed, particularly in this era of new, highly effective, direct-acting antiviral therapy for HCV infection.

Centers for Disease Control and Prevention: CDC WONDER. (accessed September 25, 2017).
Rudd RA, Seth P, David F, Scholl L: Increases in drug and opioid-involved overdose deaths – United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016; 65: 1445–1452.
Centers for Disease Control and Prevention. Statistics and Surveillance, Hepatitis C. (accessed September 22, 2017).
Onofrey S, Aneja J, Haney GA, Nagami EH, DeMaria A Jr, Lauer GM, Hills-Evans K, Barton K, Kulaga S, Bowen MJ, Cocoros N, McGovern BH, Church DR, Kim AY: Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review. Ann Intern Med 2015; 163: 254–261.
Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, Bloom RD, Nazarian SM, Sawinski D, Porrett P, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Farooqi M, Gentile C, Smith J, Reese PP: Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. N Engl J Med 2017; 376: 2394–2395.
Durand C, Brown D, Wesson R, Bhair N, Naqvi F, Ostrander D, Bowring M, Massie A, Rasmussen S, Sugarman J, Segev D, Sulkowski M, Desai N: EXPANDER-1: exploring renal transplants using hepatitis-C infected donors for HCV-negative recipients. Am J Transplant 2017; 17(suppl 3).
Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, Port FK, Sung RS: A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation 2009; 88: 231–236.
Wei F, Liu J, Liu F, Hu H, Ren H, Hu P: Interferon-based anti-viral therapy for hepatitis C virus infection after renal transplantation: an updated meta-analysis. PLoS One 2014; 9:e90611.
Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV: Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One 2016; 11:e0158431.
Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD: Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 2016; 16: 1588–1595.
Fernandez I, Munoz-Gomez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, Arias A, Prieto M, Castells L, Cuervas-Mons V, Hernandez O, Crespo J, Calleja JL, Forns X, Londono MC: Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol 2017; 66: 718–723.
Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, Massetto B, Brainard DM, McHutchison JG, Bourliere M, Peck-Radosavljevic M, Manns M, Pol S: Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med 2017; 166: 109–117.
Scalea JR, Barth RN, Munivenkatappa R, Philosophe B, Cooper M, Whitlow V, LaMattina JC: Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation 2015; 99: 1192–1196.
Sibulesky L, Javed I, Reyes JD, Limaye AP: Changing the paradigm of organ utilization from PHS increased-risk donors: an opportunity whose time has come? Clinical Transplant 2015; 29: 724–727.
Reese PP, Abt PL, Blumberg EA, Goldberg DS: Transplanting hepatitis C-positive kidneys. N Engl J Med 2015; 373: 303–305.
Goldberg DS, Blumberg E, McCauley M, Abt P, Levine M: Improving organ utilization to help overcome the tragedies of the opioid epidemic. Am J Transplant 2016; 16: 2836–2841.
Kimmel PL, Fwu CW, Abbott KC, Eggers AW, Kline PP, Eggers PW: Opioid prescription, morbidity, and mortality in United States dialysis patients. J Am Soc Nephrol 2017; 28: 3658–3670.
Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL: Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol 2017; 12: 287–297.
Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M: Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405–412.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.